Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -3.36 is 89% below its 5-year average of -1.77, near the low end of its 5-year range (-3.36–-0.12).
279.66% below its 12-month average of -0.89.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.93.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 28 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T19:08:19.964Z. Historical observations retain their original dates. Historical series through 2026-03-16.
EARNINGS PER SHARE (EPS)
-3.36
EARNINGS PER SHARE (EPS) AVG TTM
-0.89
EARNINGS PER SHARE (EPS) AVG 3Y
-1.69
EARNINGS PER SHARE (EPS) AVG 5Y
-1.77
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-279.66%
CURRENT VS 3Y AVG
-99.11%
CURRENT VS 5Y AVG
-89.30%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Stoke Therapeutics, Inc.
Market Cap
$1.57B
Earnings Per Share (EPS)
-3.36
TTM Avg
-0.89
3Y Avg
-1.69
5Y Avg
-1.77
Market Cap
$1.54B
Earnings Per Share (EPS)
4.10
TTM Avg
2.19
3Y Avg
2.59
5Y Avg
2.64
Market Cap
$1.54B
Earnings Per Share (EPS)
-2.52
TTM Avg
-3.51
3Y Avg
-3.12
5Y Avg
-2.29
Market Cap
$1.61B
Earnings Per Share (EPS)
0.84
TTM Avg
0.16
3Y Avg
0.00
5Y Avg
0.42
Market Cap
$1.61B
Earnings Per Share (EPS)
-2.67
TTM Avg
-2.43
3Y Avg
-2.07
5Y Avg
-2.07
Market Cap
$1.61B
Earnings Per Share (EPS)
-4.04
TTM Avg
-4.19
3Y Avg
-4.39
5Y Avg
-2.20
Market Cap
$1.52B
Earnings Per Share (EPS)
25.28
TTM Avg
10.68
3Y Avg
-22.38
5Y Avg
-5.21
Market Cap
$1.62B
Earnings Per Share (EPS)
-1.42
TTM Avg
-1.32
3Y Avg
-1.19
5Y Avg
-1.40
Market Cap
$1.62B
Earnings Per Share (EPS)
4.63
TTM Avg
1.23
3Y Avg
0.09
5Y Avg
-0.82
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | $1.57B | -3.36 | -0.89 | -1.69 | -1.77 |
| Innoviva, Inc. (INVA)vs › | $1.54B | 4.10 | 2.19 | 2.59 | 2.64 |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -2.52 | -3.51 | -3.12 | -2.29 |
| Omnicell, Inc. (OMCL)vs › | $1.61B | 0.84 | 0.16 | 0.00 | 0.42 |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.61B | -2.67 | -2.43 | -2.07 | -2.07 |
| uniQure N.V. (QURE)vs › | $1.61B | -4.04 | -4.19 | -4.39 | -2.20 |
| Nutex Health, Inc. (NUTX)vs › | $1.52B | 25.28 | 10.68 | -22.38 | -5.21 |
| Ocular Therapeutix, Inc. (OCUL)vs › | $1.62B | -1.42 | -1.32 | -1.19 | -1.40 |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 4.63 | 1.23 | 0.09 | -0.82 |
| Septerna Inc (SEPN)vs › | $1.63B | -0.54 | -1.52 | -1.00 | -1.00 |
Trailing EPS (TTM)
$-3.36
Forward EPS (Est.)
$-3.62
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.12 |
| 2024-12-31 | -1.65 |
| 2023-12-31 | -2.38 |
| 2022-12-31 | -2.60 |
| 2021-12-31 | -2.34 |
| 2020-12-31 | -1.56 |
| 2019-12-31 | -1.59 |
| 2018-12-31 | -0.53 |
| 2017-12-31 | -0.24 |
